XML 18 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6
Business and Product Line Acquisitions - Additional Information (Detail) (USD $)
 3 Months Ended 9 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended
Feb. 28, 2013
Feb. 29, 2012
Feb. 28, 2013
Feb. 29, 2012
Jun. 30, 2011
GeneSeek, Inc.
Apr. 01, 2010
GeneSeek, Inc.
May 31, 2012
GeneSeek, Inc.
May 31, 2011
GeneSeek, Inc.
Feb. 28, 2013
GeneSeek, Inc.
Apr. 01, 2010
GeneSeek, Inc.
Minimum
Apr. 01, 2010
GeneSeek, Inc.
Maximum
Jun. 30, 2011
GeneSeek, Inc.
First Year Contingent Payment
Jun. 30, 2011
GeneSeek, Inc.
Payment for Inventory Purchased and Other Liabilities
Jun. 21, 2011
VeroMara
May 01, 2012
Merial Limited.
Oct. 01, 2012
Macleod Pharmaceuticals
Jan. 02, 2013
Scidera Genomics,LLC
Business Acquisition [Line Items]                                  
Cash consideration for purchase of business           $ 14,050,000               $ 813,000 $ 3,200,000 $ 9,918,000 $ 3,400,000
Contingent consideration potential payment           7,000,000               200,000      
Allocation of purchase price for accounts receivable           1,923,000                   353,000  
Allocation of purchase price for inventory           1,512,000                   1,238,000  
Allocation of purchase price for fixed assets           847,000                 340,000 300,000 246,000
Allocation of purchase price for current liabilities           905,000                   82,000  
Allocation of purchase price for deferred tax liabilities           2,530,000                   748,000  
Allocation of purchase price for contingent consideration potential payment           3,583,000   4,370,000 1,487,000           600,000 100,000  
Other intangible assets estimated lives (years)                   5 years 20 years            
Contingent consideration payment term           3 years                      
Change in purchase consideration 40,000 (180,000) 92,000 (180,000)       787,000                  
Contingent consideration payment         1,856,000   1,263,000         1,537,000 319,000        
Allocation of purchase price for contingent consideration potential payment, adjustment             154,000                    
Estimated revenues from acquisitions                           800,000      
Purchase price allocation for current assets                             335,000   35,000
Purchase price allocation for intangible assets                             3,125,000    
Purchase price allocation for goodwill and intangible assets                               $ 8,957,000 $ 3,119,000